share_log

Sanofi Says Phase 2 Trial of Frexalimab in Relapsing Multiple Sclerosis Shows Significant Reduction in Disease Activity

Sanofi Says Phase 2 Trial of Frexalimab in Relapsing Multiple Sclerosis Shows Significant Reduction in Disease Activity

赛诺菲说,Frexalimab治疗复发性多发性硬化症的2期试验显示疾病活性显著降低
MT Newswires ·  2023/05/31 19:35

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发